CLS participates in the ”10th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer” in the Netherlands

Clinical Laserthermia Systems AB (publ) participates in the ”10th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer” in Noordwijk, in the Netherlands, on 11-13 February. The conference is about using focal therapy and advanced diagnostic imaging, when treating cancer in prostate and kidney, and is primarily addressing urologists. 

CLS will present a poster titled ”Characterization of TRANBERG | Laser Applicator of diffuser type for Focal Laser Ablation in prostate cancer”,  describing the results from ex-vivo tests with focal laser ablation (FLA) using CLS’ proprietary TRANBERG® |Laser Applicator, none-cooled, diffuser. The poster will be available on the CLS website after the presentation at the conference has taken place.

- In addition to the poster presentation we will showcase and demonstrate the TRANBERG system together with our single use accessories. Dr. Eric Walser from University of Texas, Medical Branch, who has chosen CLS’ single-use products for standard use in his FLA treatments, will also be attending the conference. Dr. Walser will be presenting results from his study regarding FLA treatment of prostate cancer. Our products were not used in this study, but the clear focus on FLA treatment is promising and supports CLS’ market position, said Karin Peterson, Chief Product Officer at CLS.

Previous meetings have attracted some 200 participants from all over the world. Read more about the conference, which is organized by Société Internationale d'Urologie (SIU:  Symposium on Focal Therapy and Imaging

*Tests made on tissue in an external environment, separated from the organism

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se